When Trade Secret Injunctions Become Patent Noncompetes

A recent U.S. Court of Appeals for the Federal Circuit decision applying California trade secret law offers a timely reminder that published patent materials cannot easily be recast as trade secrets. In International Medical Devices, Inc. v. Cornell, the Federal Circuit reversed trade-secret liability and vacated related damages and injunctive relief after concluding that the plaintiffs had not shown protectable trade secrets under the California Uniform Trade Secrets Act.

In a separate recent California ruling, later adopted at hearing, a court confronted a recurring question at the intersection of trade secret law, employee mobility, and patent practice: when does a secrecy injunction become a patent noncompete? The employer sought relief that extended beyond protecting confidential information—requesting restrictions that would effectively bar a former inventor from assisting others in challenging, designing around, or evaluating patents he had worked on. That request highlights a critical boundary: protecting genuine secrets is one thing; restraining lawful patent-related work is another.

The connection between the two rulings is important. In both, the party seeking trade secret protection tried to push the doctrine beyond actual secrecy and into territory occupied by public knowledge, patent disclosures, or ordinary professional experience. Cornell addresses that problem from the liability side: information disclosed in patents, available in published materials, or generally known in the field cannot be turned into a trade secret merely by labeling it confidential. The California injunction ruling addresses the same problem from the remedy side: even where narrow protection for genuine secrets is appropriate, trade secret law should not be used to restrain a former technical employee from using public information, general expertise, or ordinary patent-law tools such as invalidity analysis, design-around work, and claim-scope evaluation. Together, the rulings draw the same line from opposite directions: secrecy can be protected, but public knowledge and professional skill cannot be converted into a patent noncompete.

California Trade Secret Law Should Not Do the Work of a Noncompete

The body of California trade secret law already reflects an important distinction: a former employee’s familiarity with technology, criticism of a patent, or continued work in the same field does not automatically amount to misappropriation. That distinction matters in patent-heavy employment disputes, where employers sometimes try to frame the former insider’s technical sophistication itself as the danger. The better question is not whether the former employee understands the patents unusually well. The better question is whether he is using actual trade secrets, privileged material, or wrongfully obtained confidential documents in a way the law forbids. If accepted, this theory would allow any patent-heavy employer to convert trade secret law into a de facto noncompete—precisely the outcome California law is designed to prevent.

FLIR and the Line Between Patent Disagreement and Trade Secret Misconduct

That principle is reflected in FLIR Systems, Inc. v. Parrish. There, the California Court of Appeal recognized that a former employee-inventor’s dispute over the validity of patent applications did not, by itself, amount to threatened trade secret misappropriation. The significance of FLIR is not merely procedural. It reflects a deeper policy judgment that disagreement over whether a patent should issue, or whether it is valid as written, is not the same thing as stealing confidential information. In other words, an inventor’s challenge to a patent position may be adverse to the assignee’s interests without being an act of unfair competition.

The. Cornell decision reinforces the same boundary under California trade secret law. The court emphasized that material disclosed in patents or otherwise publicly available does not qualify for trade-secret protection, and that patent disclosures can make alleged secrets generally known even if the disclosed concepts were never commercialized in real-world products. The decision is especially relevant in patent-heavy trade secret disputes because it prevents parties from recasting public-domain patent information, generally known technical concepts, or self-evident variations of known art as proprietary secrets merely because those concepts later become important in a competitive dispute. It also underscores the danger of using trade secret law to restrain ordinary patent-related work: when the relevant knowledge is already public, generally known, or readily ascertainable, the remedy is not a trade secret injunction but ordinary patent-law analysis.

Mere Possession Is Not the Same as Misuse

The same logic cautions against overreading mere possession of work-related files. California law has long distinguished between improper use and bare possession. That does not mean document retention is irrelevant, and employers are not powerless when confidential materials are wrongfully taken. Cases such as Pillsbury, Madison & Sutro v. Schectman show that courts may order the return of improperly removed confidential documents when there is concrete proof of misappropriation. But that is a narrower proposition than claiming that a former employee’s possession of project materials—or his familiarity with prosecution history, technical data, and litigation positions—justifies forbidding future work for adverse parties. Especially in real-world research and development settings, inventors and senior technical personnel often accumulate project materials across email accounts, cloud platforms, home offices, and personal devices unless strict and consistently enforced company policies say otherwise.

Why Most Invalidity Theories Do Not Depend on Secret Know-How

The deeper problem with the employer’s theory is that it assumes a former inventor is uniquely dangerous as a patent challenger merely because he understands the science and prosecution history better than outsiders. But most common invalidity theories do not depend on confidential know-how in the first place. Section 101 asks whether the claims are directed to patent-eligible subject matter under governing doctrine. There is nothing proprietary about whether claims satisfy the Alice framework or whether they merely claim what occurs in nature. Recent eligibility cases such as ChromaDex v. Elysium Health, Payoneer, and REGENXBIO only underscore how unsettled and court-driven that area remains.

The same is generally true for Sections 102 and 103. Those theories usually rise or fall on prior art, printed publications, public uses, sales, and legal comparison between the claims and what was already known. The duty of candor and disclosure already requires inventors, prosecutors, and others substantively involved in prosecution to disclose material information to the U.S. Patent and Trademark Office (USPTO) during examination, up to issuance, and in relevant post-allowance or reexamination settings. For that reason, one should be cautious before assuming that a former inventor must possess some secret body of undisclosed knockout prior art. That premise would suggest a candor problem, not a proper foundation for an anti-competition-style injunction.

Section 112 is a partial variation, but not a complete one. Written description, enablement, possession of the full scope, and related disclosure issues can certainly implicate facts known to inventors. Even so, Section 112 challenges are ordinarily framed as legal and evidentiary questions about the specification and the claims, not as exercises in exploiting proprietary competitive know-how. Likewise, prior-sale and public-use issues often concern commercial facts that may be known at least as well—or better—by the employer than by the inventor.

Is the Inventor Uniquely Able to “Circumvent” a Patent?

The request to bar the former inventor from helping others “circumvent” the patent may be the most revealing feature of all, because “circumvent” is not even a recognized concept in patent law. In practice, it could sweep in perfectly lawful conduct: identifying alternative formulations, suggesting design-arounds, analyzing claim scope, or helping a third party assess whether its product falls outside the claims. Infringement is a legal conclusion, not a taboo subject, and freedom-to-operate analysis is a routine and legitimate function of patent professionals. None of that strips the patentee of its rights; if the patent owner believes the conduct still infringes, it remains free to sue and press its preferred claim construction. Likewise, it is entirely normal for competitors and former inventors to improve on existing technology and seek new patent protection, even where those improvements raise difficult line-drawing questions about infringement. Those disputes are resolved through ordinary patent doctrine, not by forbidding technical people from participating in the analysis. A ban on helping others “circumvent” a patent therefore risks suppressing lawful design-around work and non-infringement advice under the vague banner of confidentiality.

Inventorship Is the Important Caveat

Inventorship is the major caveat to any claim that former inventors never possess uniquely important information. Unlike Sections 101, 102, and 103, inventorship often turns on first-hand evidence of conception: who actually contributed to the claimed subject matter, who did not, and at what level of specificity. U.S. patent law does not make someone an inventor merely because he supervised a project, funded the work, proposed a goal, or held a senior title. Inventorship turns on contribution to conception of the claimed invention. In that sense, a named or omitted inventor may indeed possess uniquely valuable information about who actually invented what. The USPTO candor rules are straightforward however: known errors in inventorship (whether at or after the filing) must be submitted to the USPTO, not held secret.

That caveat, however, does not rescue the broader injunction theory. Facts about conception are not the same thing as trade secrets. They are often historical facts about legal authorship of the claimed invention. That type of information is not proprietary in the commercial sense—it is foundational to determining legal inventorship. And in practice, many inventors are not well positioned to police inventorship or when applications are filed. Scientists and engineers are often unfamiliar with the legal boundaries of inventorship under U.S. law. Some are pushed to accept honorary inventors, strategic additions, or business-driven inventorship decisions. Others fail to object simply because they do not realize that contribution to conception—not status, supervision, or general support—is the governing legal standard. If anything, that reality shows why courts should be especially cautious before treating later inventorship-related assistance as unfair competition.

Assignor Estoppel Shows the Patent System Already Knows How to Handle This

Assignor estoppel further illustrates why inventor-led patent challenges cannot be treated as inherently wrongful. The doctrine exists precisely because inventors sometimes later challenge patents they assigned. Patent law has long recognized that possibility, which is why courts developed a limited equitable doctrine to police contradictory representations in litigation. As reaffirmed by the Supreme Court in Minerva Surgical, Inc. v. Hologic, Inc., assignor estoppel is not a blanket bar. It applies only when the assignor’s later invalidity position contradicts explicit or implicit representations made in the assignment. That framework itself confirms that inventor challenges are not alien to the patent system. They are common enough to require doctrine about when they may proceed and when they may not.

That matters here for two reasons. First, assignor estoppel is a targeted patent-law doctrine; it does not give employers a free-floating right to punish or enjoin former employees merely because they later question the strength of patents they once worked on. Second, patent validity is not frozen at the moment an inventor signs an oath, declaration, or assignment. New prior art may later be discovered. Claims may later be amended. Courts may later interpret eligibility doctrine differently than applicants, examiners, or prior tribunals did. At worst for the inventor in a particular case, an estoppel argument may prevent a specific invalidity defense. That does not transform later validity questions into trade secret misuse or unfair competition.

The point is even clearer in post-grant practice. Assignor estoppel does not broadly prohibit inventor participation in administrative or judicial proceedings. Inventors may still appear as witnesses, provide technical testimony, or assist in evaluating patent strength, although their testimony may receive heavier scrutiny when it conflicts with prior statements and is not adequately corroborated. The patent system already has tools to address inconsistency and credibility. Trade secret law need not be stretched to do the work of excluding former inventors from the field.

The Right Distinction

Against that doctrinal backdrop, the recent California ruling is especially noteworthy. The court was willing to impose narrow interim restrictions aimed at preserving the status quo: limits directed to trade secrets, attorney-client communications, work product, and certain non-public materials. But it refused to go further and convert those concerns into a broad restraint on future patent-related work. That distinction is exactly the right one. This is not to deny the legitimacy of protecting genuine trade secrets or protected confidential materials; the concern arises only when such theories are extended to restrain lawful patent-related activity and trade.

The broader lesson is simple. A former inventor’s technical sophistication, familiarity with prosecution history, or willingness to revisit the validity of patents he once worked on does not by itself make him a trade secret threat. Protecting genuine secrets is one thing. Restraining lawful future consulting, testimony, inventorship challenges, prior-art analysis, design-around work, or other patent-related activity is another. When courts police that line carefully, they protect both legitimate confidentiality interests and the patent system’s equally important function: allowing patents to be tested, challenged, corrected, and, where appropriate, invalidated.

Image Source: Deposit Photos
Author: jamesgroup
Image ID: 13471174